Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 10Observational 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 11Stomach Neoplasms 6Neoplasms 5Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myositis 2Lung Neoplasms 2Cholangiocarcinoma 2Vascular Complications 1Sjogren's Syndrome 1Scleroderma, Systemic 1Sarcopenia 1Recurrence 1Rectal Neoplasms 1Plaque, Atherosclerotic 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Melanoma 1Lupus Erythematosus, Systemic 1Lung Diseases, Interstitial 1Liver Neoplasms 1Influenza, Human 1Immune-Related Adverse Events 1

Interventions

Radiotherapy, Intensity-Modulated 5Docetaxel 4Cisplatin 4Radiation 2Positron Emission Tomography Computed Tomography 2Immunotherapy 2Fluorouracil 2Drug Therapy 2sintilimab 1neodymium pyrocatechin disulfonate 1X-Rays 1Restraint, Physical 1Quality of Life 1Patient Reported Outcome Measures 1Parenteral Nutrition 1Molecular Diagnostic Techniques 1Liquid Biopsy 1Induction Chemotherapy 1Immune Checkpoint Inhibitors 1Gemcitabine 1G(M1) Ganglioside 1Enteral Nutrition 1Endoscopy 1DMAC2L protein, human 1Chemoradiotherapy 1Capecitabine 1Blood Specimen Collection 1Biopsy 1Biological Therapy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Nasopharyngeal Carcinoma × Immune Checkpoint Inhibitors × Clear all
NCT07618078 2026-06-03

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting
900 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡